KEYTRUDA: A Game-Changer in Non-Small Cell Lung Cancer Treatment

Lung cancer remains one of the most prevalent and deadly forms of cancer worldwide, with non-small cell lung cancer (NSCLC) being the most common type. The treatment options for NSCLC have evolved significantly over the years, with immunotherapy playing a crucial role in recent times. KEYTRUDA is a groundbreaking medication that has revolutionized the way we treat NSCLC.

Neoadjuvant and Adjuvant Treatment

KEYTRUDA is indicated for the treatment of patients with resectable NSCLC (tumors ≥4 cm or node positive) in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent therapy after surgery. This approach has shown promising results in terms of improved overall survival and response rates.

Metastatic NSCLC Treatment

KEYTRUDA is also approved for the treatment of patients with metastatic NSCLC whose tumors express programmed death ligand 1 (PD-L1) as determined by an FDA-approved test, following disease progression on or after platinum-containing chemotherapy. Additionally, KEYTRUDA can be used as a single agent in patients with stage III NSCLC where surgery is not feasible.

First-Line Treatment

KEYTRUDA has also been approved for first-line treatment of patients with NSCLC expressing PD-L1, without EGFR or ALK genomic tumor aberrations. In combination with carboplatin and either paclitaxel or paclitaxel protein-bound, KEYTRUDA is indicated for the first-line treatment of metastatic squamous NSCLC. Furthermore, KEYTRUDA in combination with pemetrexed and platinum chemotherapy is approved for the first-line treatment of metastatic nonsquamous NSCLC patients without EGFR or ALK genomic tumor aberrations.

KEYTRUDA has emerged as a key player in the fight against non-small cell lung cancer. Its versatility and efficacy make it an attractive option for treating various stages and types of NSCLC. By understanding the different treatment options available, including KEYTRUDA's indications and combinations, healthcare providers can make informed decisions to provide the best possible outcomes for their patients.

Keynote 189 clinical trial